• Filter By Topic

April 8, 2021

Reproductive Decision-Making in Families Containing Multiple Individuals With Epilepsy

Beliefs about genetic causes of epilepsy contribute to concerns and decisions to limit childbearing. These beliefs should be addressed in genetic counseling to ensure that true risks to offspring and reproductive options are well understood. 

April 8, 2021

The SANTÉ Study at 10 Years of Follow-Up: Effectiveness, Safety, and Sudden Unexpected Death in Epilepsy

The long-term efficacy and safety profiles of the deep brain stimulation (DBS) system for epilepsy are favorable and demonstrate stable outcomes.

related news
April 8, 2021

CURE Epilepsy Update: April 2021

This month we are fortunate to have many opportunities to more formally recognize so many members of our epilepsy community.

April 7, 2021

Adult Phenotype of KCNQ2 Encephalopathy

Seizure frequency declines over the years and most patients are seizure-free in adulthood. Motor, language and behavioral problems are an issue of continuous concern.

April 6, 2021

Stiripentol in the Treatment of Adults With Focal Epilepsy: A Retrospective Analysis

Stiripentol seems to be a useful option in the treatment of patients with severely pharmacoresistant epilepsy.

related news
April 5, 2021

Epilepsy During the COVID-19 Pandemic Lockdown: A US Population Survey

The COVID-19 pandemic presents unique challenges to PWE, including increased seizure rates, problems with access and cost of life-saving medications.

April 1, 2021

COVID-19-Associated Seizures May Be Common, Linked to Higher Risk of Death

Seizures can happen in patients with COVID-19 critical illness, even those without any prior neurologic history, and that they are associated with worse outcomes.

March 31, 2021

Psychological Status After Insulo-Opercular Resection in Patients With Epilepsy: Depression, Anxiety, and Quality of Life

Employment status and seizure control, but not location of surgery, significantly predicted quality of life.

March 30, 2021

Epilepsy Surgery: Late Seizure Recurrence After Initial Complete Seizure Freedom

Complete resection of the MRI lesion is the most important factor to maintain long-term seizure freedom.

March 30, 2021

Valproate Usage in Pregnancy: An Audit From the Kerala Registry of Epilepsy and Pregnancy

Safe and effective antiepileptic drugs as alternatives to valproate are the need of the hour.

March 29, 2021

Metformin Trial Dramatically Reduces Seizures in Tuberous Sclerosis

A team of researchers led by UCL Great Ormond Street Institute of Child Health (ICH) and Great Ormond Street Hospital (GOSH) has found that metformin - a drug commonly used to treat Type 2 diabetes - can successfully reduce symptoms associated with tuberous sclerosis complex (TSC), including reduction in the frequency of seizures and the size of brain tumors. The study, which also included teams from Royal United Hospitals Bath NHS Foundation Trust (RUH) and University Hospitals Bristol and Weston NHS Foundation Trust, recruited 51 patients with TSC who were randomly assigned a placebo or metformin for one year on a dose similar to that given for Type 2 diabetes. Throughout the study, the research team wanted to see if metformin, which inhibits the mTOR (cellular growth) pathway, could limit the tumour growth and epilepsy associated with TSC. All patients involved in the study had tumors in the kidney known as renal angiomyolipomas (AML). Of the 51 who took part, 27 patients had tumors in the brain called subependymal giant cell astrocytomas (SEGA) and 21 of them were under assessment for seizure frequency. Over the course of the year, the team found a 21% reduction in the size of brain tumors of those who were given metformin, compared to a 3% increase in tumor volume for those taking the placebo. Patients with epilepsy and taking metformin saw a 44% drop in the frequency of their seizures, compared to a drop of only 3% for those on the placebo.

March 26, 2021

Status Epilepticus and COVID-19: A Systematic Review

Status epilepticus can be a neurological manifestation of SARS-CoV-2 (COVID-19) infection. Systemic inflammatory syndrome due to cytokine release could play a role in COVID-19-related SE.

1 2 132


    Join our email list for the
    latest epilepsy research news,
    discoveries, and more.